Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $17.39, but opened at $18.04. Sysmex shares last traded at $17.27, with a volume of 3,428 shares traded.
Sysmex Price Performance
The company has a quick ratio of 2.30, a current ratio of 2.97 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $10.86 billion, a price-to-earnings ratio of 30.80 and a beta of 1.14. The company's 50-day simple moving average is $17.27 and its 200 day simple moving average is $18.11.
Sysmex (OTCMKTS:SSMXY - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.04). The business had revenue of $958.89 million for the quarter, compared to analyst estimates of $991.22 million. Sysmex had a return on equity of 11.81% and a net margin of 10.56%. Equities research analysts forecast that Sysmex Corporation ADR will post 0.57 EPS for the current year.
Sysmex Company Profile
(
Get Free Report)
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Read More
Before you consider Sysmex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.
While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.